Search results for "bioinformatic"

showing 10 items of 1651 documents

2017

Aqueous humour (AH) is an important biologic fluid that maintains normal intraocular pressure and contains proteins that regulate the homeostasis of ocular tissues. Any alterations in the protein compositions are correlated to the pathogenesis of various ocular disorders. In recent years, gender-based medicine has emerged as an important research focus considering the prevalence of certain diseases, which are higher in a particular sex. Nevertheless, the inter-gender variations in the AH proteome are unknown. Therefore, this study endeavoured to characterize the AH proteome to assess the differences between genders. Thirty AH samples of patients who underwent cataract surgery were categoriz…

0301 basic medicineMultidisciplinaryFuture studiesAqueous humourInflammationBiologyProteomicsBioinformaticsPathogenesis03 medical and health sciences030104 developmental biologyImmune systemProteomebiology.proteinmedicineAntibodymedicine.symptomPLOS ONE
researchProduct

Taste Disturbance with Acetazolamide

1997

03 medical and health sciences0302 clinical medicinebusiness.industrymedicineMEDLINEPharmacology (medical)030204 cardiovascular system & hematologyAcetazolamidebusinessBioinformatics030226 pharmacology & pharmacymedicine.drugTaste disturbanceAnnals of Pharmacotherapy
researchProduct

Hemoglobin Level Analysis in Hemodialysis Patients Treated With Erythropoiesis Stimulating Agents

2010

In this chapter authors try to develop an expert system with the help of neural network method like Organizing Maps (SOMs) for hemodialysis patient.  Neural network models play a very important role for data analysis of hemodialysis patients with end-stage renal disease.  There are two main goals: firstly, the knowledge extraction from a database using Self-Organizing Maps (SOMs); and secondly, to provide an accurate prediction of Hb levels next month.

business.industrymedicine.medical_treatmentmedicineErythropoiesisHemoglobinHemodialysisbusinessBioinformatics
researchProduct

Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?

2012

Mantle Cell Lymphoma (MCL) is associated with a dismal prognosis. Recently, along with the improved understanding of the pathophysiology of this disease, new first line regimens have been established and in addition novel treatment options have entered the clinical arena. In consequence, prognosis of the disease has fortunately improved. We here focus on the rationale, current clinical knowledge and future concepts of Temsirolimus, an inhibitor of mTOR, in the treatment of MCL. At this time this drug has been shown to be effective as single agent for relapsed disease and early combination data show promising results. In addition, with a brief outline of other treatment options, we aim to g…

Oncologymedicine.medical_specialtybusiness.industryFirst linemantle cell lymphomaCancerTreatment optionsmTOR-inhibitorReviewDiseasemedicine.diseaseBioinformaticslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282TemsirolimusClinical knowledgeOncologyInternal medicinetemsirolimusmedicineRefractory Mantle Cell LymphomaMantle cell lymphomabusinessmedicine.drugClinical Medicine Insights: Oncology
researchProduct

Novel Approaches for Glioblastoma Treatment: Focus on Tumor Heterogeneity, Treatment Resistance, and Computational Tools

2019

BACKGROUND: Glioblastoma (GBM) is a highly aggressive primary brain tumor. Currently, the suggested line of action is the surgical resection followed by radiotherapy and treatment with the adjuvant temozolomide (TMZ), a DNA alkylating agent. However, the ability of tumor cells to deeply infiltrate the surrounding tissue makes complete resection quite impossible, and in consequence, the probability of tumor recurrence is high, and the prognosis is not positive. GBM is highly heterogeneous and adapts to treatment in most individuals. Nevertheless, these mechanisms of adaption are unknown. RECENT FINDINGS: In this review, we will discuss the recent discoveries in molecular and cellular heterog…

Cancer Researchmedicine.medical_treatmentDNA Mutational AnalysisBrain tumorBioinformaticsComplete resectionTumor heterogeneityCancer VaccinesMicrotubulesArticleClonal EvolutionMachine LearningGenetic HeterogeneityCancer stem cellAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentMedicineHumansTreatment resistancePrecision MedicineDNA Modification MethylasesImmune Checkpoint InhibitorsTemozolomideModels Geneticbusiness.industryBrain NeoplasmsTumor Suppressor ProteinsBrainComputational BiologyChemoradiotherapy Adjuvantmedicine.diseasePrognosisRadiation therapyDNA Repair EnzymesOncologyDrug Resistance NeoplasmMutationTumor Suppressor Protein p53businessGlioblastomaGlioblastomamedicine.drug
researchProduct

Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge

2017

Statins, the 3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase inhibitors, are widely prescribed for treatment of hypercholesterolemia. Although statins are generally well tolerated, up to ten percent of statin-treated patients experience myalgia symptoms, defined as muscle pain without elevated creatinine phosphokinase (CPK) levels. Myalgia is the most frequent reason for discontinuation of statin therapy. The mechanisms underlying statin myalgia are not clearly understood. To elucidate changes in gene expression associated with statin myalgia, we compared profiles of gene expression in skeletal muscle biopsies from patients with statin myalgia who were undergoing statin re-challenge (cases)…

Male0301 basic medicinemyalgiaGene Expressionlcsh:MedicineApoptosis030204 cardiovascular system & hematologyPathology and Laboratory MedicineBioinformaticsBiochemistry0302 clinical medicineMedicine and Health SciencesGene Regulatory Networkslcsh:ScienceMusculoskeletal SystemEnergy-Producing OrganellesMyositisRegulation of gene expressionMultidisciplinaryCell DeathbiologyMusclesDrugsMiddle AgedMitochondriaCell ProcessesHMG-CoA reductaseFemalelipids (amino acids peptides and proteins)AnatomyCellular Structures and Organellesmedicine.symptomResearch ArticleSenescencemedicine.medical_specialtyStatinmedicine.drug_classPainBioenergeticsPolymorphism Single Nucleotide03 medical and health sciencesSigns and SymptomsDiagnostic MedicineInternal medicineGeneticsmedicineHumansGene Regulationcardiovascular diseasesMuscle SkeletalAgedPharmacologybusiness.industrylcsh:RStatinsBiology and Life SciencesComputational Biologynutritional and metabolic diseasesMyalgiaCell Biologymedicine.disease030104 developmental biologyEndocrinologyGene Expression RegulationSkeletal MusclesLeukocytes Mononuclearbiology.proteinProtein prenylationlcsh:QHydroxymethylglutaryl-CoA Reductase InhibitorsSLCO1B1businessPLOS ONE
researchProduct

The emergence of drug resistance to targeted cancer therapies: Clinical evidence.

2019

For many decades classical anti-tumor therapies included chemotherapy, radiation and surgery; however, in the last two decades, following the identification of the genomic drivers and main hallmarks of cancer, the introduction of therapies that target specific tumor-promoting oncogenic or non-oncogenic pathways, has revolutionized cancer therapeutics. Despite the significant progress in cancer therapy, clinical oncologists are often facing the primary impediment of anticancer drug resistance, as many cancer patients display either intrinsic chemoresistance from the very beginning of the therapy or after initial responses and upon repeated drug treatment cycles, acquired drug resistance deve…

0301 basic medicineDrugCancer Researchmedicine.drug_classmedicine.medical_treatmentmedia_common.quotation_subjectTranslational researchApoptosisDrug resistanceMonoclonal antibodyBioinformatics03 medical and health sciences0302 clinical medicineNeoplasmsmedicineHumansPharmacology (medical)Hedgehog ProteinsEpigeneticsProtein Kinase Inhibitorsmedia_commonPharmacologyChemotherapybusiness.industryCancerImmunotherapyProtein-Tyrosine Kinasesmedicine.disease030104 developmental biologyInfectious DiseasesOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisbusinessProteasome InhibitorsDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
researchProduct

Polymorphisms of an innate immune gene, toll-like receptor 4, and aggressive prostate cancer risk: a systematic review and meta-analysis.

2014

Background: Toll-like receptor 4 (TLR4) is one of the best known TLR members expressed on the surface of several leukocytes and tissue cells and has a key function in detecting pathogen and danger-associated molecular patterns. The role of TLR4 in the pathophysiology of several age-related diseases is also well recognized, such as prostate cancer (PCa). TLR4 polymorphisms have been related to PCa risk, but the relationship between TLR4 genotypes and aggressive PCa risk has not been evaluated by any systematic reviews. Methods: We performed a systematic review and meta-analysis of candidate-gene and genome-wide association studies analyzing this relationship and included only white populatio…

MaleProstate cancer polymorphisms of TLR4 aggressive prostate cancer risk meta-analysisSystematic Reviewslcsh:MedicineGenome-wide association studySingle-nucleotide polymorphismBiologyResearch and Analysis MethodsBioinformaticsPolymorphism Single NucleotideProstate cancerGenotypeGeneticsCancer GeneticsmedicineHumansSettore MED/05 - Patologia ClinicaGenetic Predisposition to DiseaseStatistical Methodslcsh:ScienceGenotypingGenetic associationEvolutionary BiologyMultidisciplinarylcsh:RProstatic NeoplasmsBiology and Life SciencesResearch Assessmentmedicine.diseaseImmunity InnateToll-Like Receptor 4Systematic reviewMeta-analysisPhysical SciencesGenetic Polymorphismlcsh:QPopulation GeneticsMathematicsStatistics (Mathematics)Genome-Wide Association StudyResearch ArticleMeta-AnalysisPLoS ONE
researchProduct

Unknown primary tumors

2011

An unknown primary tumor (UPT) is defined by the presence of a metastatic cancer without a known primary site of origin despite a standardized diagnostic workup. Clinically, UPTs show rapid progression and early dissemination, with signs and symptoms related to the metastatic site. The molecular bases of their biology remain largely unknown, with no evidence as to whether they represent a distinct biological entity. Immunohistochemistry remain the best diagnostic tool in term of cost-effectiveness, but the time-consuming "algorithmic process" it relies on has led to the application of new molecular techniques for the identification of the primary site of UPTs. For example, several microarra…

Cancer Researchbusiness.industryGene Expression ProfilingBiological entityMEDLINETreatment optionsSigns and symptomsBioinformaticsFunctional imagingMicroRNAsOncologyUnknown primary tumors UPTImmunologyUnknown Primary TumorsGeneticsUnknown primaryAnimalsHumansNeoplasms Unknown PrimaryMedicinebusinessSite of originBiochimica et Biophysica Acta (BBA) - Reviews on Cancer
researchProduct

Endometrial Receptivity Analysis (ERA): data versus opinions

2021

Abstract This article summarises and contextualises the accumulated basic and clinical data on the ERA test and addresses specific comments and opinions presented by the opponent as part of an invited debate. Progress in medicine depends on new technologies and concepts that translate to practice to solve long-standing problems. In a key example, combining RNA sequencing data (transcriptomics) with artificial intelligence (AI) led to a clinical revolution in personalising disease diagnosis and fostered the concept of precision medicine. The reproductive field is no exception. Translation of endometrial transcriptomics to the clinic yielded an objective definition of the limited time period …

0301 basic medicine030219 obstetrics & reproductive medicineendometrial receptivitybusiness.industryNatural cycleHormonal replacement therapyEmbryoimplantation / recurrent implantation failureDiseaseEndometriumPrecision medicineBioinformaticsAcademicSubjects/MED00905Embryo transfer03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureDebate ContinuedmedicineendometriumEndometrial receptivitybusinessembryo transferHuman Reproduction Open
researchProduct